Impact of Liver Metastases on Outcomes With Chemotherapy or Immune Checkpoint Inhibitors in Pancreatic Cancer
Einfluss von Lebermetastasen auf Outcomes unter Chemotherapie oder Immun-Checkpoint-Inhibitoren bei Pankreaskarzinom
Immunity, Inflammation and Disease · 2026-10 · 14 (10)
DOI: 10.1002/iid3.70545 ↗Auf einen Blick
Bei fortgeschrittenem Pankreaskarzinom war unter Chemotherapie das Überleben bei Lebermetastasen kürzer; unter Immun-Checkpoint-Inhibitoren zeigten sich keine signifikanten Unterschiede.
Fragestellung
Welchen Einfluss haben Lebermetastasen auf die Outcomes bei fortgeschrittenem Pankreaskarzinom unter Chemotherapie oder Immun-Checkpoint-Inhibitoren?
Methode
Post-hoc-Survivalanalysen aus einer chemotherapiebasierten Studie und ICI-Studien; Stratifizierung nach Lebermetastasen.
Ergebnisse
In der Chemotherapie-Kohorte war das Gesamtüberleben mit Lebermetastasen kürzer: 7,0 Monate (95 %-KI 6,0–8,8) vs. 12,0 Monate (8,7–18,0; log-rank p = 0,002). Das progressionsfreie Überleben war ebenfalls reduziert: 5,0 Monate (3,6–5,7) vs. 7,5 Monate (5,4–9,0; p = 0,016).
Schlussfolgerung der Autor:innen
Lebermetastasen waren bei Pankreaskarzinom unter Chemotherapie mit kürzerem OS und PFS verbunden. Unter ICI wurde kein Überlebenseffekt der Lebermetastasen beobachtet.
Kernaussagen
- Chemotherapie: OS mit Lebermetastasen 7,0 Monate vs. 12,0 Monate ohne
- PFS mit Lebermetastasen 5,0 Monate vs. 7,5 Monate
- Unter ICI kein signifikanter Unterschied im OS
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Beobachtungsstudie in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 06.10.2026. Verfasst von Laura K Kjær und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Liver Neoplasms, Pancreatic Neoplasms. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Herlev and Gentofte Hospital, Denmark.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Pancreatic cancer (PC) is on the rise worldwide, with significant improvements in survival rates still awaited. Most patients are diagnosed at an advanced stage, often with liver metastases (LM), associated with poor prognosis and immunosuppression. This study aimed to evaluate the impact of LM on outcomes in patients with advanced PC treated with chemotherapy or immune checkpoint inhibitors (ICIs). Material and Methods We performed post‐hoc survival analyses using data from a chemotherapy‐based study (ClinicalTrials.gov ID: NCT02767557) ( n = 147) and ICI‐based studies (NCT04258150, NCT02866383, and NCT05116917) ( n = 129). Patients were stratified based on the presence of LM. Exploratory analyses within the LM subgroup were adjusted for absolute lymphocyte counts (ALCs), neutrophile‐lymphocyte‐ratios (NLRs), interleukin (IL)−6, IL‐8, carbohydrate antigen 19‐9, C‐reactive protein, and YKL‐40.
Results
In the chemotherapy cohort, overall survival (OS) was significantly lower in patients with LM ( n = 107) (7.0 months, 95% confidence interval (CI): 6.0–8.8) compared to those without LM ( n = 40) (12.0 months, 8.7–18.0; log‐rank p = 0.002). Progression‐free survival (PFS) was similarly reduced in the LM group (5.0 months, 3.6–5.7) versus the non‐LM group (7.5 months, 5.4–9.0; p = 0.016). In the ICI cohort, no significant differences in OS were observed between patients with ( n = 111) and without LM ( n = 18). Adjusted analyses indicated that higher IL‐6 and YKL‐40 were associated with increased mortality risk in patients receiving chemotherapy.
Discussion
LM were associated with significantly shorter OS and PFS in patients with PC receiving chemotherapy. No survival impact of LM was observed in patients treated with ICIs. These findings highlight the need to consider metastatic burden when stratifying treatment outcomes in future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
- National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
- Department of Medicine, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark.
ORCID-Profile: Laura K Kjær, Kasper Madsen
Förderung
- Herlev and Gentofte Hospital, Denmark
Zitieren
APA
Kjær, L. K., Theile, S., Madsen, K., Johansen, J. S., Holmström, M. O., Andersen, M. H., & Chen, I. M. (2026). Impact of Liver Metastases on Outcomes With Chemotherapy or Immune Checkpoint Inhibitors in Pancreatic Cancer. Immunity, Inflammation and Disease, 14(10). https://doi.org/10.1002/iid3.70545
Vancouver
Kjær LK, Theile S, Madsen K, Johansen JS, Holmström MO, Andersen MH, et al. Impact of Liver Metastases on Outcomes With Chemotherapy or Immune Checkpoint Inhibitors in Pancreatic Cancer. Immunity, Inflammation and Disease. 2026;14(10). doi:10.1002/iid3.70545
BibTeX
@article{Kjr2026,
author = {Kjær, Laura K and Theile, Susann and Madsen, Kasper and Johansen, Julia S and Holmström, Morten Orebo and Andersen, Mads Hald and Chen, Inna M},
title = {Impact of Liver Metastases on Outcomes With Chemotherapy or Immune Checkpoint Inhibitors in Pancreatic Cancer},
journal = {Immunity, Inflammation and Disease},
year = {2026},
volume = {14},
number = {10},
doi = {10.1002/iid3.70545}
}
EUVIMED